Novo Nordisk acquires Ziylo in $800m deal to advance diabetes treatment

Novo Nordisk, a leading Danish pharmaceutical company, has completed a significant acquisition of Ziylo, a biotechnology spin-out from the University of Bristol, for a deal ... Read More